Your Testosterone Went Up. The Interesting Question Is Which Part of It.
In June 2026 a poster at the Endocrine Society annual meeting produced a run of headlines about weight-loss drugs raising testosterone and improving sperm quality in men with obesity. The underlying work was a systematic search of the randomized literature, and what it found was genuinely worth reporting. It was also five trials, three of which had data in a form that could be combined, and the largest single finding was a 28 percent rise in total testosterone over 24 weeks. Total testosterone is the number nearly every man gets back from a lab, and it is also the number most likely to move for reasons that have nothing to do with how much testosterone the body is making. What follows is a look at what those trials measured, why the mechanism is almost certainly the weight rather than the drug, and which endpoint in the whole dataset is the one actually worth watching. This is educational background on an area of active research. GLP-1 receptor agonists are not approved for hypogonadism or male infertility, and nothing here is medical advice.
What the Pooled Analysis Actually Pooled
The work presented at ENDO 2026 came from a team at University Hospitals Coventry and Warwickshire and Warwick Medical School, led by Pratibha Natesh. They searched PubMed and the Cochrane Library for randomized trials of GLP-1 receptor agonists in men aged 18 to 65 with an appropriate comparator arm. Five trials met the criteria. Three of them reported data in a form that could be combined quantitatively. Across those, men on GLP-1 therapy showed improvements in testosterone, sperm count, and sperm size and shape. That is the finding, and it is a reasonable one. It is worth being precise about what it is not. It is not a trial designed to test whether GLP-1 drugs treat hypogonadism, because no such trial has been run. It is a retrospective look at hormone and semen measures that were collected alongside other endpoints in studies built to answer different questions. Natesh's own framing was about clinical direction rather than about the drug, arguing the results support treating the underlying metabolic problem in men whose low testosterone tracks their body weight, rather than reaching first for replacement therapy. That argument does not depend on the drug being special. It depends on the weight coming off.
The Evidence Base Behind the Headline
A systematic search of PubMed and the Cochrane Library turned up five randomized trials in men aged 18 to 65 that met the inclusion criteria, and only three of those carried data in a form the authors could combine. The two described in any detail were open-label, meaning everyone involved knew who was receiving what. None of that makes the finding wrong. It does mean the headline rests on a narrower base than the coverage suggested.
The Trial With the Comparator That Mattered
The most informative of the studies ran 24 weeks in men who had obesity, type 2 diabetes and functional hypogonadism, and randomized them to semaglutide or to intramuscular testosterone. Head-to-head against actual replacement therapy is a hard test, and semaglutide came out of it with improvements in total testosterone, in hypogonadal symptoms, and in the proportion of sperm with normal morphology, which moved from about 2 percent to about 4 percent. Total testosterone rose roughly 28 percent from baseline. The detail that separates this from a simple hormone result is what happened to luteinizing hormone and follicle-stimulating hormone, which stayed roughly where they started. Injected testosterone does the opposite. It raises circulating testosterone while the pituitary reads the higher level, dials back its own signal, and spermatogenesis quiets down with it. Getting a hormonal improvement without that shutdown is the whole point of the finding. A separate 16-week open-label trial of liraglutide in men with obesity and functional hypogonadism reported increases in total testosterone alongside increases in LH and FSH, which points the same direction and slightly more strongly.
What Changed Over 24 Weeks of Semaglutide
Percent change from baseline in men who had obesity, type 2 diabetes and functional hypogonadism. Total testosterone rose roughly 28 percent while the pituitary signals above it held steady rather than falling, which is the opposite of what happens on injected testosterone. The morphology bar is a doubling of a very small number, from 2 percent of sperm judged normally shaped to 4 percent, and reads far more dramatically as a percentage than it does as an absolute.
Why Body Fat Suppresses the Signal in the First Place
The reason any of this works is not mysterious. Adipose tissue is endocrine tissue, and one of the things it expresses is aromatase, the enzyme that converts testosterone into estradiol. More fat mass means more conversion, and the resulting estradiol feeds back on the hypothalamus and pituitary to reduce the signal telling the testes to produce. Insulin resistance, which travels with visceral fat, adds its own suppression at the hypothalamic level. Visceral fat is also inflammatory, and inflammatory signalling interferes with Leydig cell function directly. The net result is a man whose testes are structurally fine producing less than they otherwise would, which is what the term functional hypogonadism is describing. Functional in this context means the cause sits upstream and is potentially reversible, as distinct from primary testicular failure, where it is not. Remove enough fat mass and you remove the aromatase, the inflammatory load and part of the insulin resistance at once. The axis recovers because the thing suppressing it left. Any drug that reliably produces meaningful weight loss should therefore produce this effect, and the older bariatric surgery literature confirms that it does.
Total Testosterone Is a Slipperier Number Than It Looks
Here is where the headline gets complicated. Testosterone circulates in three states. Roughly 44 percent is bound tightly to sex hormone-binding globulin and is not available to tissue. Roughly 54 percent is bound loosely to albumin. Around 2 percent circulates free. A total testosterone assay counts all of it, including the large fraction that is locked up. Obesity suppresses SHBG, and weight loss raises it back. Bariatric data show SHBG climbing by as much as 21 nmol/L after surgery, and total testosterone climbing alongside it. Some of that total increase is more testosterone being produced. Some of it is more carrying capacity in the blood holding testosterone that would otherwise have been cleared. Those two things look identical on a total testosterone report and are not remotely the same physiologically. What a man actually experiences depends on the free and bioavailable fractions, and the trials in this analysis reported total. This does not mean the finding is an artifact. Free testosterone does generally rise with substantial weight loss, and symptom scores improved in the semaglutide trial, which is a harder endpoint to fake. It means the 28 percent figure overstates the change in usable hormone by an amount nobody has quantified here.
Where Circulating Testosterone Actually Sits
A total testosterone result measures every molecule in the sample, and in a typical adult male only about 2 percent of it is unbound and directly available to tissue. Most of the rest is locked to sex hormone-binding globulin. Weight loss raises SHBG, which raises the total by increasing carrying capacity, so a rising total figure does not by itself establish that the usable fraction moved with it.
The Route Matters Less Than the Amount
Weight-loss research has been measuring this relationship for years, and the pattern is consistent across methods. A meta-analysis comparing interventions found that diet-driven loss averaging 9.8 percent of body weight raised total testosterone by about 2.9 nmol/L, roughly 84 ng/dL. Surgical weight loss averaging 32 percent raised it by about 8.7 nmol/L, roughly 251 ng/dL. Three times the weight loss, three times the hormonal effect, with nothing about the mechanism of weight loss appearing to matter. A 2025 umbrella review of systematic reviews reached the same conclusion, with the strongest evidence sitting behind post-surgical increases in LH, FSH and SHBG. Set the GLP-1 number against that scale and it lands exactly where the weight loss would predict. If a man starts at 300 ng/dL, a 28 percent rise is 84 ng/dL, the same figure the diet studies produce. That correspondence is the most useful thing in the dataset, and it argues that GLP-1 drugs are not doing anything to the reproductive axis that a sufficiently effective diet would not do. They are just considerably better at producing the weight loss in the first place.
The Route Matters Less Than the Kilograms
Pooled data put diet-driven loss of roughly 10 percent of body weight at about 84 ng/dL of added total testosterone, and surgical loss of around 32 percent at about 251 ng/dL. The middle bar is arithmetic rather than a measured pooled value: a 28 percent rise from a 300 ng/dL starting point works out to the same 84 ng/dL as the diet figure, which is what you would expect if the mechanism is the weight rather than the molecule.
What the Arithmetic Predicts for a Given Loss
Longer cohort data give a rule of thumb worth carrying around. Followed to 36 months, total testosterone rose about 0.6 percent for each kilogram of body weight lost. A man who drops 15 kg would expect something near a 9 percent increase on that basis. Someone starting at 340 ng/dL would land around 370, which is a real improvement and is also not a transformation. To reach the kind of number people picture when they imagine fixing low testosterone through weight loss, you generally need the sort of loss that used to require surgery, which is precisely why the newer agents changed the conversation. A 20 percent total body weight reduction is now achievable pharmacologically in a way it was not a decade ago, and 20 percent of a 110 kg man is 22 kg, which the rule of thumb puts at roughly 13 percent more total testosterone. Two caveats belong with that estimate. It is an average across a cohort, and the spread around cohort averages in hormone research is wide enough that individual results routinely land at double or half the predicted value. It is also linear, and the underlying biology is not, since the relationship has to flatten once fat mass stops being what limits production.
Roughly Half a Percent Per Kilogram
Cohort data followed to 36 months put the average gain at about 0.6 percent of total testosterone for every kilogram of body weight lost. Drawn as a straight line it gives a usable rule of thumb for what a given amount of weight loss tends to produce. Real biology is not a straight line, the relationship almost certainly flattens once fat mass stops being the limiting factor, and an average across a cohort says nothing about where any single man will land.
- Expected gain in total testosterone
The Fertility Signal Is the More Interesting One
Strip out the testosterone headline and something more clinically useful is sitting underneath it. The standard approach to a man with obesity and a low testosterone reading has often been replacement therapy, and replacement therapy suppresses spermatogenesis. That is not a rare side effect or a dosing problem, it is the expected pharmacology, and for a man in his thirties or forties who has not finished having children it is a significant cost that frequently goes underexplained at the point of prescription. The signal in these trials runs the other way. Sperm counts and morphology improved rather than declined, and the pituitary signals held steady rather than shutting down. There had also been genuine concern in the andrology literature about whether GLP-1 drugs might harm semen parameters, given how rapid weight loss and caloric restriction can affect reproductive function, and the accumulated data now argue against that worry. Medscape's coverage summarized the position as fertility not harmed and possibly helped, which is a fair reading. The improvements are almost certainly indirect, driven by the weight rather than the receptor, and 2 percent to 4 percent normal morphology is still a low number in absolute terms.
Where This Evidence Is Thin
Five randomized trials is a small base, and the two described in any detail were open-label, which means participants and investigators both knew the assignment. Open-label design matters more than usual here because two of the endpoints, hypogonadal symptom scores and anything self-reported, are exactly the measures most sensitive to knowing you are on the new treatment. The follow-up periods were 16 and 24 weeks. A full cycle of spermatogenesis takes about 74 days, so 24 weeks covers roughly two cycles, which is adequate to detect a change and short of what you would want to know whether it holds. Nobody has tested whether the hormonal gains persist through the weight regain that commonly follows discontinuation, and the honest expectation is that they do not, since the mechanism is the fat mass. There is also the muscle question, which sits awkwardly alongside all of this. Rapid weight loss on these drugs takes lean mass along with fat, and lean mass loss is not helpful for a man optimizing hormonal health. That tension between the metabolic benefit and the body composition cost is a real one, and it is the reason resistance training and protein intake keep appearing in every serious discussion of this drug class.
Reading Your Own Numbers Without Getting Ahead of Them
If a single testosterone reading came back low, the first useful step is a second one, drawn in the morning, since the diurnal swing is large enough to move a man across a diagnostic threshold by itself. A total testosterone value in isolation cannot tell you much. LH and FSH indicate whether the problem sits in the testes or upstream, SHBG tells you how to interpret the total, and estradiol is informative in a man carrying significant fat mass. That panel is what separates weight-driven functional hypogonadism, the situation this entire body of research addresses, from primary testicular failure, which weight loss will not fix. The distinction determines what to do next and cannot be made from the number most people are handed. None of the drugs discussed here are approved for low testosterone or for infertility. Prescribing one for weight management in a man who also has metabolic disease is an ordinary clinical decision with an established evidence base; expecting it to serve as hormone therapy is not. The version of this that holds up is unglamorous and well supported: in men whose testosterone is low because of their weight, losing the weight raises it, and how the weight comes off appears to matter far less than whether it does.
Frequently Asked Questions
Have more questions? Contact us or explore our full peptide intelligence platform.
Related Articles
Tribulus Is Sold as a Testosterone Booster. Eight of Ten Trials in Men Found No Change in Male Hormones, and the Erection Benefit It Does Show Arrives Without a Testosterone Rise.
Does tribulus raise testosterone? Eight of ten trials in men found no change. A 180-man trial did show better erections. What the research found, plus safety.
Three Beers a Night for Three Weeks Cut Testosterone by About 7 Percent. The Bigger Cost to Men Who Train Shows Up in the Muscle.
Does alcohol lower testosterone? In a diet-controlled trial, about 40 grams of alcohol a day for three weeks lowered testosterone in middle-aged men by 6.8 percent. Heavy drinking lowers it far more, and alcohol after training cut muscle protein synthesis by 24 to 37 percent. An educational review of the dose, the timing and what a month off actually changes.
16:8 Fasting Loses About the Same Weight as Counting Calories. The Early Window and the Muscle Question Are What Actually Differ.
In four randomized trials, an 8-hour eating window produced between 2.3 kg more and 0.8 kg less weight loss than its comparison diet. The 12-month NEJM trial found no significant edge over calorie restriction. An early 7 am to 3 pm window did better, and one trial in trained men saw testosterone fall. An educational review of the time-restricted eating evidence for men.